Clinical trial
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem…
NCT00321932 · University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00321932 |
|---|---|
| Title | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant |
| Official title | A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation |
| Lead sponsor | University of Minnesota, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer |
| Intervention type | Dietary Supplement, Drug |
| Interventions | calcium, cholecalciferol, zoledronic acid |
| Enrollment | 61 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2012 |
| First posted | May 4, 2006 |
| Last update posted | Mar 9, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: